Latest Regulatory Approvals News

Neurizon Therapeutics has formally responded to the FDA's clinical hold on its lead ALS drug NUZ-001, submitting new animal safety data. The company aims to join the HEALEY ALS Platform Trial by late 2025, pending regulatory approval.

Octava Minerals secures $1.5 million in a placement to fund exploration and due diligence for acquiring the historically promising Federation copper-zinc-silver project in Western Tasmania.

Orpheus Uranium has secured a Native Title Mining Agreement with the Wilyakali people, unlocking advanced exploration at its Radium Hill South and Mundaerno projects. This milestone sets the stage for drilling approvals expected by late 2025.

BlinkLab is advancing its FDA 510(k) clinical trials for autism and ADHD diagnostics, completing its U.S. autism pilot phase and expanding European ADHD recruitment. A recent $7.66 million capital raise supports these efforts as the company targets regulatory approvals in 2026.

Dimerix has secured a significant licensing agreement with Amicus Therapeutics for its kidney disease drug candidate DMX-200 in the US, receiving a US$30 million upfront payment and advancing its Phase 3 trial with FDA endorsement of a key clinical endpoint.

Peak Rare Earths Limited has updated its acquisition scheme, replacing Ganzhou Chenguang with Shenghe Resources (Singapore) Pte. Ltd. as the acquiring party, simplifying regulatory hurdles and valuing the company at nearly A$158 million.

Echo IQ has secured a strategic collaboration with the Mayo Clinic Platform and raised $17.3 million, advancing its AI-driven cardiology tools towards FDA clearance and US commercial scale.

AVJennings Limited’s acquisition scheme has received Supreme Court approval, triggering share suspension and a scheduled delisting from ASX and SGX.

The Foreign Investment Review Board has approved CoStar Group’s acquisition of Domain Holdings, clearing a major regulatory hurdle ahead of the shareholder vote scheduled for August 4.

PointsBet Holdings Limited has issued a Target’s Statement recommending shareholders accept MIXI Australia’s $1.20 per share all-cash takeover offer, highlighting a significant premium and rejecting a rival scrip bid from Betr Entertainment.

Santana Minerals reports a robust update to its Bendigo-Ophir Gold Project with a new Pre-Feasibility Study showing enhanced economics and streamlined mine design, alongside advancing regulatory approvals in New Zealand.

Zelira Therapeutics has locked in a $650,000 loan facility secured against its anticipated FY25 R&D tax rebate, aiming to accelerate its HOPE SPV clinical trial and strengthen working capital.